Leukaemias and cancers following iodine-131 administration for thyroid cancer
Author Information
Author(s): F de Vathaire, M Schlumberger, MJ Delisle, C Francese, C Challeton, E de la Genardiere, F Meunier, C Parmentier, C Hill, H Sancho-Garnier
Primary Institution: National Institute of Health and of Medical Research
Hypothesis
What is the risk of leukaemia and solid cancers following iodine-131 treatment for thyroid cancer?
Conclusion
The study found no cases of leukaemia among patients treated with iodine-131, but identified a significant risk of colorectal cancer related to the cumulative activity of iodine-131 administered.
Supporting Evidence
- No cases of leukaemia were observed among the 1497 patients exposed to iodine-131.
- 80 patients developed a solid second malignant neoplasm, with colorectal cancer being significantly related to iodine-131 activity.
- The overall excess relative risk of second cancer per estimated effective sievert received was 0.38.
Takeaway
Doctors gave a special medicine to help thyroid cancer patients, and they found that while no one got leukaemia, some patients did get a type of colon cancer.
Methodology
The study analyzed 1771 patients treated for thyroid cancer, excluding those who received external radiotherapy, and followed them for an average of 10 years.
Potential Biases
The study excluded patients who received external beam radiotherapy, which could introduce bias in assessing cancer risk.
Limitations
The follow-up period was relatively short, averaging 10 years, which may not capture long-term cancer risks.
Participant Demographics
21% of the participants were male, with a mean age of 40 years at diagnosis.
Statistical Information
P-Value
0.1
Confidence Interval
90% CI - 0.22 to 1.2
Statistical Significance
p=0.02
Want to read the original?
Access the complete publication on the publisher's website